Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The potential of microRNAs (miRNAs) as molecular tumor biomarkers for early diagnosis and prognosis in lung cancer is still unclear.
Objective: To analyze expression of miRNAs in A549 lung adenocarcinoma (LUAD) cells and in primary, non-malignant bronchial epithelial (BE) cells from healthy donors. To analyze the most prominently deregulated miRNAs in plasma samples of LUAD patients and healthy donors.
Materials And Methods: The expression of 752 miRNAs in LUAD and BE cells was assessed by RT-qPCR with mean-centering restricted normalization. The relative plasma levels of 18 miRNAs in LUAD patients and healthy donors were analyzed using RT-qPCR and normalized to miR-191-5p and miR-16-3p. Putative interactions between miRNAs and their target genes were investigated in silico.
Results: Out of 752 miRNAs, 37 miRNAs were significantly deregulated in A549 cells compared to BE cells. MiR-15b-3p, miR-148a-3p, miR-193b-3p, and miR-195-5p were significantly deregulated in plasma samples of LUAD patients compared to donors. The target genes of those four miRNAs are involved in essential mechanisms in cancer development and progression.
Conclusions: There are substantial differences between cancer and control miRNA expression in vitro and in plasma samples of LUAD patients compared to healthy donors. Four deregulated miRNAs are promising as a diagnostic biomarker for adenocarcinoma of the lung.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/CBM-210205 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic impact and characteristics of ROS1 fusion in patients with surgically resected lung adenocarcinoma.
Lung Cancer
September 2025
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, PR China. Electronic address:
Objective: We aimed to investigate the prognostic significance of ROS1 fusion in surgically resected lung adenocarcinoma (LUAD).
Materials And Methods: Consecutive patients who underwent complete resection and ROS1 testing between 2015 and 2020 were included. Propensity score matching (1:2) was applied to balance baseline characteristics.
Impact of rare EGFR exon 19 insertion-deletion variants on tyrosine kinase inhibitor efficacy in non-small-cell lung cancer: a 5-year multicenter analysis.
ESMO Open
September 2025
Department of Pulmonary and Critical Care Medicine, Fuzong Clinical Medical College of Fujian Medical University & The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, China. Electronic address:
Background: The clinical impact of rare epidermal growth factor receptor (EGFR) exon 19 insertion-deletion (19delins) variants on tyrosine kinase inhibitor (TKI) efficacy remains poorly characterized. We updated 5-year outcomes to evaluate long-term survival and optimal treatment strategies in advanced lung adenocarcinoma (LUAD) patients harboring these mutations.
Materials And Methods: In this multicenter prospective study, 36 treatment-naive advanced LUAD patients with EGFR 19delins mutations received first-generation (n = 26) or third-generation TKIs (n = 10).
Development and Validation of a Pathomics-Based Prognostic Model for Patients with Lung Adenocarcinoma Undergoing First-Line EGFR-TKI Therapy.
Ann Surg Oncol
September 2025
Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Background: Accurate prognostic prediction is crucial for personalized treatment of patients with lung adenocarcinoma (LUAD) receiving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This study aims to develop and validate a pathomics-based prognostic model for EGFR-TKI-treated patients with LUAD.
Patients And Methods: Data from 122 patients with LUAD who underwent first-line EGFR-TKI therapy were retrospectively analyzed.
Lung cancer is the most common cause of cancer-related death worldwide. Recent advancements in targeted therapies and immunotherapies have achieved remarkable success. However, patient responses to treatments with lung cancer vary substantially.
View Article and Find Full Text PDFDUSP11 is an intracellular innate immune checkpoint in lung adenocarcinoma.
Cancer Immunol Res
September 2025
University of Missouri, Columbia, Missouri, United States.
The discovery of immune checkpoints and the rapid growth of immuno-oncology (IO) have sparked efforts to utilize the immune system to treat a wide range of cancer types/subtypes. While the major focus of IO over the past decades has been to manipulate the adaptive immune system, recent attention has been given to manipulating the innate immune system to treat cancer and/or to enhance adaptive responses. Here, we detailed the intracellular protein, Dual Specificity Phosphatase 11 (DUSP11), as an innate immune checkpoint (iIC) in Non-Small Cell Lung Cancer (NSCLC) adenocarcinoma (LUAD).
View Article and Find Full Text PDF